Related Experiment Videos
Infliximab in refractory coeliac disease
Rakesh Chaudhary1, Subrata Ghosh
1Gastroenterology Section, Imperial College London, Hammersmith Hospital, UK.
European Journal of Gastroenterology & Hepatology
|May 10, 2005
Summary
Most coeliac disease patients manage well with a gluten-free diet. However, some refractory cases may benefit from anti-tumour necrosis factor (anti-TNF) therapies, offering new insights into disease mechanisms.
Area of Science:
- Gastroenterology
- Immunology
Background:
- Coeliac disease (CD) is typically managed with a gluten-free diet (GFD).
- A subset of CD patients exhibit refractory disease, necessitating alternative treatments.
- The role of anti-tumour necrosis factor (anti-TNF) agents in CD pathogenesis and treatment is under investigation.
Purpose of the Study:
- To explore the potential of anti-TNF agents in managing refractory coeliac disease.
- To investigate the implications of anti-TNF therapy response on understanding CD pathogenesis.
- To examine the mechanisms of action of anti-TNF agents in the context of CD.
Main Methods:
- Literature review on refractory coeliac disease and anti-TNF therapy.
- Analysis of clinical case studies involving anti-TNF agents in CD patients.
- Discussion of immunological pathways implicated in coeliac disease and anti-TNF action.
Main Results:
- Refractory coeliac disease presents a significant clinical challenge.
- Anti-TNF agents have shown promise in select cases of refractory CD.
- Patient response to anti-TNF therapy provides insights into disease mechanisms.
Conclusions:
- Anti-TNF therapy is a potential therapeutic option for carefully selected patients with refractory coeliac disease.
- Further research into anti-TNF agents can elucidate coeliac disease pathogenesis and treatment strategies.
- Optimizing treatment for refractory CD requires a nuanced understanding of patient response and disease mechanisms.